As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Silence Therapeutics Plc. The largest reported stake is Richard Griffiths', at 7.97%. 7 filings are on record since February 9, 2026 (Schedule 13D/A, August 13, 2026).
Sell to companies like Silence Therapeutics Plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 13,180,206 · Shared voting: 0 · Sole dispositive: 13,180,206 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-05
- · Reporting person: Tetragon Financial Group Limited · Sole voting: 0 · Shared voting: 9,878,565 · Sole dispositive: 0 · Shared dispositive: 9,878,565 · SCHEDULE 13G/A, 2026-10-13
- · Holder: Tetragon Financial Group Limited · Percent: 5.2% · SCHEDULE 13G
- · Reporting person: Richard Griffiths · Sole voting: 14,391,498 · Shared voting: 0 · Sole dispositive: 14,391,498 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-13
- · Reporting person: Invus Public Equities, L.P. · Sole voting: 8,707,287 · Shared voting: 0 · Sole dispositive: 8,707,287 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
Silence Therapeutics Plc has 7 Schedule 13D or 13G filings on record since 2026-02-09. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 7.97% | 14,391,498 | SCHEDULE 13D/A, 2026-08-13 | 2026-08-12 | |
| Fmr LLC | 7.1% | 13,180,206 | SCHEDULE 13G, 2026-11-05 | 2026-09-30 |
| 7% | 9,934,314 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 | |
| Tetragon Financial Group Limited | 5.3% | 9,878,565 | SCHEDULE 13G/A, 2026-10-13 | 2026-10-05 |
| Lombard Odier Asset Management (USA) Corp | 4.2% | 5,935,955 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-31 |
Holding shares or following this stake? See who's behind Silence Therapeutics Plc and the warning signs.
Free to see. No signup.
Keep reading
More on Silence Therapeutics Plc and the records around it.
Silence Therapeutics Plc elsewhere on the record
Companies that share a holder
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Silence Therapeutics Plc
Get an email when Silence Therapeutics Plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Silence Therapeutics Plc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Silence Therapeutics Plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Silence Therapeutics Plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Richard Griffiths | 14,391,498 | 0 | 14,391,498 | 0 | SCHEDULE 13D/A, 2026-08-13 |
| Fmr LLC | 13,180,206 | 0 | 13,180,206 | 0 | SCHEDULE 13G, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 13,180,206 | 0 | SCHEDULE 13G, 2026-11-05 |
| Invus Public Equities, L.P. | 8,707,287 | 0 | 8,707,287 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Invus Public Equities Advisors, LLC | 8,707,287 | 0 | 8,707,287 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Invus Global Management, LLC | 8,707,287 | 0 | 8,707,287 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Siren, L.L.C. | 8,707,287 | 0 | 8,707,287 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Avicenna Life Sci Master Fund LP | 1,227,027 | 0 | 1,227,027 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Avicenna Life Sci Master GP LLC | 1,227,027 | 0 | 1,227,027 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Ulys, L.L.C. | 1,227,027 | 0 | 1,227,027 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Raymond Debbane | 9,934,314 | 0 | 9,934,314 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Tetragon Financial Group Limited | 0 | 9,878,565 | 0 | 9,878,565 | SCHEDULE 13G/A, 2026-10-13 |
| Tetragon Financial Management LP | 0 | 9,878,565 | 0 | 9,878,565 | SCHEDULE 13G/A, 2026-10-13 |
| Patrick G. G. Dear | 0 | 9,878,565 | 0 | 9,878,565 | SCHEDULE 13G/A, 2026-10-13 |
| Reade E. Griffith | 0 | 9,878,565 | 0 | 9,878,565 | SCHEDULE 13G/A, 2026-10-13 |
The latest filing identifies Silence Therapeutics Plc by CUSIP G8128Y157 and gives its principal executive office as 12 HAMMERSMITH GROVE, OFFICE 205, LONDON (SCHEDULE 13G, 2026-11-05).
What the percentages are based on
As of June 30, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page.Raymond Debbane, SCHEDULE 13G/A, 2026-08-13
Source of funds (Item 3)
Mr. Griffiths sold an aggregate of 5,484,320 ADSs in open market transactions between August 10, 2026 and August 12, 2026 for aggregate sales proceeds of $87.7M.Richard Griffiths, SCHEDULE 13D/A, 2026-08-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-09 | Lombard Odier Asset Management (USA) Corp | 4.2% | SCHEDULE 13G/A |
| 2026-07-08 | Richard Griffiths | 21.7% | SCHEDULE 13D/A |
| 2026-08-13 | Richard Griffiths | 7.97% | SCHEDULE 13D/A |
| 2026-08-13 | Raymond Debbane | 7% | SCHEDULE 13G/A |
| 2026-10-13 | Tetragon Financial Group Limited | 5.2% | SCHEDULE 13G |
| 2026-10-13 | Tetragon Financial Group Limited | 5.3% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 7.1% | SCHEDULE 13G |
Questions about who owns Silence Therapeutics Plc
Who owns Silence Therapeutics Plc?
On this page, 4 holders' latest ownership filings report 5% or more of Silence Therapeutics Plc: Richard Griffiths (7.97%, Schedule 13D/A, filed 2026-08-13), Fmr LLC (7.1%, Schedule 13G, filed 2026-11-05), Raymond Debbane (7%, Schedule 13G/A, filed 2026-08-13) and Tetragon Financial Group Limited (5.3%, Schedule 13G/A, filed 2026-10-13).
Who are the largest shareholders of Silence Therapeutics Plc?
By the share each holder's latest filing reports, the largest holders of Silence Therapeutics Plc on this page are Richard Griffiths (7.97%), Fmr LLC (7.1%) and Raymond Debbane (7%).
When did Richard Griffiths buy into Silence Therapeutics Plc?
The filings give report dates, not purchase dates. The earliest filing from Richard Griffiths on this page is the Schedule 13D/A, filed 2026-07-08, reporting 21.7%; its latest, Schedule 13D/A filed 2026-08-13, reports 7.97%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Silence Therapeutics Plc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 16, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Silence Therapeutics Plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.